Michel Goldman is the chief executive responsible for the management of IMI in accordance with the decisions of the Governing Board. He is supported by the staff of the Executive Office.
As the Executive Director of IMI, he builds and promotes networks of innovation, in close collaboration with all stakeholders involved in pharmaceutical R&D. He supports the launch and successful continuation of collaborative programmes to foster research and development activities on more effective and safer therapies for patients across Europe.
Michel Goldman is Professor of Immunology at the Faculty of Medicine of the Université Libre de Bruxelles (Belgium). His achievements in the fields of immune-mediated disorders and immune-based biotherapies resulted in more than 400 articles in peer-reviewed journals. In 2004, Michel Goldman started up the Institute for Medical Immunology (Charleroi, Belgium) as the first public-private partnership in the biomedical sector in Wallonia and he has been the first vice-president of the BioWin Health Cluster created to foster networks between industries and academic institutions in this region. From 2007 to 2009, he served the European Research Council as a member of the Advisory panel on Immunology and Infectious Diseases.
In 2000, Michel Goldman received the Joseph Maisin Prize, a major award for clinical sciences delivered by the Belgian Fund for Scientific Research, and he held the Spinoza chair at the University of Amsterdam in 2001. He was recognized as ISI Highly Cited Scientist by the Thomson Institute for Scientific Information in 2006. Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II (France) in 2007.